BRCA1 and BRCA2 mutations are critical in Hereditary Breast and Ovarian Cancer (HBOC) syndrome, influencing cancer risk and treatment strategies. This review synthesizes findings from recent studies on these mutations, noting that BRCA1 mutations are linked with a higher risk of breast and ovarian cancers than BRCA2. For instance, BRCA1 mutations show a lifetime breast cancer risk of 55-72% and ovarian cancer risk of 39-44%, while BRCA2 mutations show a 45-69% risk for breast cancer and 11-17% for ovarian cancer. Variability in risk estimates is attributed to differences in study design, sample size, and methodology. Large, long-term studies generally provide more stable estimates. Effective management strategies include regular screenings and preventive surgeries. Future research should focus on standardizing methodologies and considering diverse factors to enhance risk management for BRCA mutation carriers.
Chakraborty et al. (Sat,) studied this question.